sameAs
Guidelines for the use and interpretation of assays for monitoring autophagyA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityThe dual role of tumor lymphatic vessels in dissemination of metastases and immune response developmentInterleukin 15 as a promising candidate for tumor immunotherapyStatins impair antitumor effects of rituximab by inducing conformational changes of CD20MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of AutophagyDirect tumor damage mechanisms of photodynamic therapy.Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia.Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases.Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in miceIron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Interleukin 18--interferon gamma inducing factor--a novel player in tumour immunotherapy?5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.Statins impair glucose uptake in human cells.Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma ModelImmunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation.Topical ALA-PDT modifies neutrophils' chemiluminescence, lymphocytes' interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies A clinical study.Potential antitumor effects of statins (Review).Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Photodynamic therapy of cancer: an updateNatural mechanisms protecting against cancer.Statins impair glucose uptake in tumor cellsTechnology evaluation: SB-485232, GlaxoSmithKline.Prospects for p53-based cancer therapy.Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma.Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo.GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy.Danger signalling during cancer cell death: origins, plasticity and regulation.Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein responseStatins can modulate effectiveness of antitumor therapeutic modalities.Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis.Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity.Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy.Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.The influence of photodynamic therapy on the immune response.Cancer stem cells in haematological malignancies.
P50
Q21996341-9D86BF40-90A7-4300-8A57-86185007988AQ24620548-4FD19297-03D9-4A6D-A206-8EB3ADBD9C76Q26797280-D63C52D6-064C-41B5-B23A-30CBECBC7BD3Q28076945-FBCFB8DB-1267-43B4-A105-245C3DAAD2D2Q28236508-DA4E9172-75DF-4B86-B349-18390A9C998AQ28472420-A2B77B57-D14B-4B86-A67F-E78FD37D3D31Q28552218-38B706A4-CC2D-40E5-B59F-E33A2FE6BC0BQ30787032-1FA03AED-50B2-41F1-A650-6721EAD223F0Q31054571-E94C7D56-1DB4-477C-8C5C-D3D0E783E595Q33196977-C917A868-9397-45B5-B8A7-16925C6CA7D9Q33351064-F78FCBDD-9D3F-4481-BF91-3AE69AA4FDE9Q33636546-EEF2A875-73F9-4153-A024-4D193B3FB997Q33882390-B5123773-B858-4515-9C49-F5CB5194C265Q33915261-7EAD8DAC-28BD-4CBF-B5CB-4651E6FDCCA3Q34060948-8C9A92CA-9741-4FC3-8269-B77E1BABE6D9Q34419117-A38A03DF-B208-4EC1-A408-D10A189851BAQ34478543-EB972304-3A91-4CEA-96F9-33DE18EDC5C4Q35000446-FFCC603F-D777-4619-8E2B-52EA7FF329BFQ35210576-846450C1-5E6D-4630-91E9-D1FB117CC904Q35215127-A4366194-1031-4AA6-B558-BA599DF17E39Q35348485-1DB9D782-84C0-42C3-95EE-B26414E476EAQ35532394-D25FDCAD-1DB5-4E76-A632-1949EE9AC61FQ35612352-43843842-CC3A-4FE0-AA83-C0C19954D0A6Q35949773-4E6EECCF-2422-4DE4-B13D-B390AD0441CBQ36055231-BD824C08-5692-4C37-8F1B-716595B6A278Q36180624-4EDDA1E7-6289-4E4B-9E9B-AB507C962CCCQ36213094-15E06814-D257-4311-93CE-3336CC9A9AC7Q36301061-0170B4FB-2925-4AC6-8955-F01BA9F87954Q36738950-622B0F6A-5693-4DBE-8A1C-20C46DF5207BQ36915065-0D992EC7-1F07-48FE-835D-FFC2822358E7Q37062090-40156271-678B-446D-997F-6BD095E5C2F6Q37381745-33C09455-B8AE-4963-A121-029EFB6E63C7Q37448609-EC057647-E4C8-4312-9287-B427F37E15D8Q37519473-9AC4E3EC-26F3-4EE8-A2EC-33B69F72B5FBQ37689301-8333018F-0600-4158-8E83-E448F37FE545Q37707162-FD7B58F5-F307-422C-B18C-AC7EB4F92368Q37778760-85BE990A-0D72-475D-8A95-487F9C572A37Q37825142-E57ACA5E-F815-4D9A-95DB-EF10AC1E217AQ38232502-1559C0CE-ECFA-4918-B38F-DE96E7C26A30Q38359714-C9AE2B56-AB5E-4375-AFDD-AFA91390D776
P50
description
Pools onderzoeker
@nl
cercetător polonez
@ro
chercheur polonais
@fr
hulumtues
@sq
inmunólogu polacu
@ast
investigador polaco
@es
investigador polaco
@gl
investigador polonès
@ca
polnischer Immunologe
@de
polski naukowiec
@pl
name
Jakub Gołąb
@ast
Jakub Gołąb
@ca
Jakub Gołąb
@de
Jakub Gołąb
@en
Jakub Gołąb
@es
Jakub Gołąb
@fr
Jakub Gołąb
@ga
Jakub Gołąb
@gl
Jakub Gołąb
@it
Jakub Gołąb
@nl
type
label
Jakub Gołąb
@ast
Jakub Gołąb
@ca
Jakub Gołąb
@de
Jakub Gołąb
@en
Jakub Gołąb
@es
Jakub Gołąb
@fr
Jakub Gołąb
@ga
Jakub Gołąb
@gl
Jakub Gołąb
@it
Jakub Gołąb
@nl
altLabel
Jakub Adam Gołąb
@pl
Jakub Golab
@en
Jakub Golab
@sl
prefLabel
Jakub Gołąb
@ast
Jakub Gołąb
@ca
Jakub Gołąb
@de
Jakub Gołąb
@en
Jakub Gołąb
@es
Jakub Gołąb
@fr
Jakub Gołąb
@ga
Jakub Gołąb
@gl
Jakub Gołąb
@it
Jakub Gołąb
@nl
P106
P214
P1053
K-6974-2013
P1412
P1559
Jakub Gołąb
@pl
P19
P21
P214
P27
P31
P3124
P3829
P496
0000-0002-2830-5100
P569
1972-02-27T00:00:00Z
P734
P7859
viaf-164979171